Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biomarin Pharmaceutical Inc (NASDAQ:BMRN)

96.03
Delayed Data
As of 4:14pm ET
 -1.02 / -1.05%
Today’s Change
62.12
Today|||52-Week Range
118.48
-8.33%
Year-to-Date
Better Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc
12:24pm / MotleyFool.com - Paid Partner Content
Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug
Sep 20 / Zacks.com - Paid Partner Content
Does Sarepta Therapeutics Inc.'s FDA Win Make Shares a Buy?
Sep 20 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close97.05
Today’s open98.19
Day’s range94.42 - 98.19
Volume1,194,196
Average volume (3 months)1,694,773
Market cap$16.6B
Dividend yield--
Data as of 4:14pm ET, 09/28/2016

Growth & Valuation

Earnings growth (last year)-16.30%
Earnings growth (this year)-275.23%
Earnings growth (next 5 years)+25.00%
Revenue growth (last year)+16.29%
P/E ratioNM
Price/Sales19.22
Price/Book6.53

Competitors

 Today’s
change
Today’s
% change
INCYIncyte Corp+4.13+4.64%
PRGOPerrigo Company PLC+0.51+0.53%
MDVNMedivation Inc0.000.00%
VRTXVertex Pharmaceutica...-0.28-0.31%
Data as of 4:14pm ET, 09/28/2016

Financials

Next reporting dateOctober 20, 2016
EPS forecast (this quarter)-$0.39
Annual revenue (last year)$872.2M
Annual profit (last year)-$171.8M
Net profit margin-19.70%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Jean-Jacques Bienaimé
Chief Financial Officer &
Executive Vice President
Daniel K. Spiegelman
Corporate headquarters
San Rafael, California

Forecasts

Search for Jobs